Medical Access and Reimbursement in Estonia

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Psilocybin and psilocin are listed among substances prohibited for handling except as explicitly allowed by law (scheduling under Estonia’s narcotics/psychotropic substances framework). #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA is regulated as a Schedule I / prohibited psychotropic in Estonian drug law and possession/supply is penalised (administrative fines, detention or criminal sanctions for trafficking), with no routine medical reimbursement pathway. #

Esketamine (Spravato) has a centralized EU marketing authorisation (indication: adults with treatment‑resistant major depressive disorder in combination with an oral antidepressant) and is registered for supply in EU member states, including Estonia. The EMA granted the marketing authorisation on 18 December 2019. #

In practice in Estonia, Spravato is a prescription medicine that must be administered under clinical supervision (clinic setting) consistent with the EMA product information; availability in Estonia is documented in EU/market product listings that include Estonia as a supply country. Access is typically arranged through psychiatrists/approved treatment centres that can deliver the supervised dosing regimen; because Spravato is a specialist, controlled psychotropic product, treatment pathways emphasize clinic‑based administration and monitoring, consistent with EMA/SmPC risk‑mitigation measures. #

Reimbursement: there is no widely published, definitive national policy indicating universal public reimbursement of Spravato by the Estonian Health Insurance Fund for the TRD indication; in many EU countries the medicine is either funded via selective reimbursement decisions, hospital budgets, or private/out‑of‑pocket arrangements depending on national health‑technology assessment and negotiated pricing. In Estonia the common practical situation is that Spravato is accessible via prescription/clinic channels but access is constrained by specialist delivery requirements and by the absence of a broadly published, automatic public reimbursement entitlement (patients and clinics therefore typically rely on private payment, hospital/clinic special funding arrangements, or case‑by‑case reimbursement decisions). (Note: specific Haigekassa reimbursement decisions are administrative and can change; for the EMA authorisation see EMA documentation). #

Ketamine is an approved medicinal product in Estonia as an anaesthetic agent (used in hospitals/operating rooms) and therefore is legally available for licensed indications; it is also used off‑label in psychiatry (intravenous or intranasal ketamine protocols) in some private clinics for treatment‑resistant depression. As an anaesthetic its regulatory status differs from novel antidepressant indications: the product is a prescription hospital medicine and clinicians who offer off‑label ketamine for psychiatric indications do so under professional/clinical judgment rather than as a reimbursed, labelled psychiatric indication. #

Reimbursement: because ketamine is not licensed for antidepressant indications, its use for depression is typically not reimbursed by public health insurance in jurisdictions that require an authorised indication for routine reimbursement; when used as an anaesthetic in hospital settings it is covered as part of hospital care. For psychiatric off‑label administrations (IV or compounded preparations) patients commonly incur private costs or rely on specific clinic funding models. Clinicians must follow national controlled‑substance handling rules when storing and administering ketamine. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT (and simple DMT‑containing preparations) are treated as prohibited psychotropic substances under Estonia’s narcotics legislation; possession, production, or distribution is illegal except where explicitly authorised for approved research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT is covered by Estonia’s prohibition on a broad range of psychoactive tryptamines and is not available as a reimbursed medicine. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ibogaine is not part of routine medical practice in Estonia and is not reimbursed; its possession or distribution falls under national narcotics controls. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Although there is academic literature documenting ceremonial/ritual ayahuasca use in Estonia, the DMT contained in ayahuasca preparations is a controlled psychotropic substance and unregulated ceremonial importation/possession is not a lawful medical pathway; there is no routine reimbursement for ayahuasca use. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline (and mescaline‑containing cacti preparations) are covered by Estonia’s narcotics scheduling and are not reimbursed or authorised for clinical psychiatric treatment outside approved trials. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Compounds in the 2C family (for example 2C‑B) are explicitly listed in Estonia’s controlled‑substance schedules and are illegal to possess, produce, or distribute except under authorised research. #